616results about How to "Reduce activation" patented technology

Touch screen data entry accuracy can be improved utilizing a touch screen interface coupled with a computing device and a data entry-enhancing touch screen surface. The touch screen interface can include a sensory system that can be configured to detect input sensations predefined input areas displayed within a graphical user interface (GUI). The data entry-enhancing touch screen surface can include one or more focused entry depressions that can be configured to centrally direct an activation device into a user-desired input area. Each focused entry depression can be spatially aligned with a predefined input area of the GUI. The activation of additional predefined input areas of the GUI that are within close proximity to the user-desired input area can be reduced.

The present invention provides a system comprising an occupancy sensor for sensing occupancy of an area, able to activate upon sensing occupancy of the area, maintain activation when sensing continuing occupancy, to include settings therefor, and to enable self-adjusting of the settings. It includes an infrared sensor section, able to passively sense occupancy and activate a signal, continue to activate upon sensing continuing occupancy, and enable separate processing of the settings. It also includes an ultrasonic sensor section, able to actively sense occupancy, activate a signal upon sensing continuing occupancy, and enable separate processing of the settings. The occupancy sensor is able to activate when the infrared sensor section senses occupancy, and to maintain activation when either the infrared sensor section or the ultrasonic sensor section senses continuing occupancy of the area. The infrared sensor section signals and the ultrasonic sensor section signals are each independently formed and activated.

An improved demineralized bone matrix (DBM) or other matrix composition is provided that has been mixed with a stabilizing agent that acts as (1) a diffusion barrier, (2) a enzyme inhibitor, (3) a competitive substrate, or (4) a masking moiety. A diffusion barrier acts as a barrier so as to protect the osteoinductive factors found in DBM from being degraded by proteolytic and glycolytic enzymes at the implantation site. Stabilizing agents may be any biodegradable material such as starches, modified starches, cellulose, dextran, polymers, proteins, and collagen. As the stabilizing agents degrades or dissolves in vivo, the osteoinductive factors such as TGF-β, BMP, and IGF are activated or exposed, and the activated factors work to recruit cells from the preivascular space to the site of injury and to cause differentiation into bone-forming cells. The invention also provides methods of preparing, testing, and using the inventive improved osteodinductive matrix compositions.

A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided.

Methods and systems for improving nerve stimulation are disclosed and are termed enhanced transcutaneous electrical stimulation (eTENS). One embodiment can be used for enhancing the excitation properties of neural tissue. In one embodiment, systems and methods are provided to enable the selective modulation of specific (targeted) neural substrate, while minimizing the activation of adjacent (non-targeted) nervous tissue, or differentially providing different modulation signals to tissue targeted by different implants. In one embodiment, the system consists of an implant that is used to modify the extracellular potential (i.e. activating function) generated by an independent electrical stimulus generator. Certain aspects of this technology can be applied to any part of the central and peripheral nervous systems. Particular embodiments of this technology provide for therapy related to urological disorders.

Biocompatible polymeric materials capable of providing in situ release of nitric oxide (NO) included diazeniumdiolated fumed silica as a filler in a multilayer polymer structure to release NO upon contact with water (blood). The blood-contacting polymer surface is preferably multi-layered so that the NO-releasing layer, containing the diazeniumdiolated fumed silica, is shielded from blood contact by one or more top (or base) coats. When in contact with blood, the NO released at the surface of the polymer prevents platelet activation and adhesion to the surface, thereby reducing platelet consumption, risk of thrombus formation and other clinical complications associated with interactions between blood and foreign materials.

Devices, systems and methods by which the real or apparent renovascular perfusion and intrarenal pressure may be selectively and controllably increased. By selectively and controllably increasing renovascular perfusion and interstitial hydrostatic pressure when the heart is unable to pump sufficient blood or when renal perfusion is suboptimal, the present invention reduces or reverses neurohormonal activation and fluid retention, and thereby minimizes their deleterious effects on the heart, vasculature, kidneys and other body systems.

The present invention relates to a method, comprising receiving patch data via contactless communication comprising a patch for a patchable firmware and patch identification information; and patching said firmware using said patch.

A versatile pest station for use with interchangeable inserts includes a housing, a lock mechanism, a first insert, and a second insert. The housing includes a base, a lid, and an opening. The base and the lid form a cavity, and the opening provides access to the cavity. The base has a bottom surface and is configured and arranged to be securely mounted to a surface. The lock mechanism interlocks the base and the lid. The first insert is configured and arranged to fit within the cavity, and the first insert includes an entrance mechanism. The second insert is configured and arranged to fit within the cavity, and the second insert includes a snap trap. The first insert and the second insert are interchangeable for individual use with the housing, and the first insert and the second insert are elevated relative to the bottom surface of the base.

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

An input device for reducing an erroneous operation and a mobile terminal having the same are disclosed. The input device includes: a first manipulating unit that has a plurality of movement directions based on a reference position and performing an input operation corresponding to each movement direction; a second manipulating unit disposed around the first manipulating unit and inputting information in a touch (tactile) manner; and an erroneous input detecting unit, which is installed to allow detection of user touches between the first and second manipulating units, can distinguish user inputs that were not intended to be made on the second manipulating unit, by comparing the signals generated when the second manipulating unit is actually operated and the signals generated by erroneous touches made adjacent to the second manipulating unit.

A method of operating a restraint system includes classifying a collision into a collision classification, generating a protruding contact sensor output and deploying the restraint system in response to the contact sensor output and the output classification. The method may also use a pre-crash sensor with or without classification and deploy the restraint system in response to the pre-crash sensor signal and the protruding contact sensor signal.

A lens driver or lens driver circuitry for an ophthalmic apparatus comprising an electronic system which actuates a variable-focus optic is disclosed herein. The lens driver is part of an electronic system incorporated into the ophthalmic apparatus. The electronic system includes one or more batteries or other power sources, power management circuitry, one or more sensors, clock generation circuitry, control algorithms and circuitry, and lens driver circuitry. The lens driver circuitry includes one or more power sources, one or more high voltage generators and one or more switching circuits.

An improved method and system of identifying individual aerosol particles in real time. Sample aerosol particles are collimated, tracked, and screened to determine which ones qualify for mass spectrometric analysis based on predetermined qualification or selection criteria. Screening techniques include one or more of determining particle size, shape, symmetry, and fluorescence. Only qualifying particles passing all screening criteria are subject to desorption / ionization and single particle mass spectrometry to produce corresponding test spectra, which is used to determine the identities of each of the qualifying aerosol particles by comparing the test spectra against predetermined spectra for known particle types. In this manner, activation cycling of a particle ablation laser of a single particle mass spectrometer is reduced.

An Implantable Pulse Generator (IPG) includes a surgically implantable housing, a battery, a first waveform generator, a second waveform generator, a modulator, and electrodes. The IPG produces a pulse envelope, a carrier waveform, and a modulated waveform. The pulse envelope is a low frequency waveform with specific pulse width, amplitude and shape to selectively stimulate a target nerve or body part. The carrier waveform is a high frequency waveform with properties such as amplitude, frequency and the like chosen so as to overcome tissue impedance and the stimulation threshold of the target nerve. The modulated waveform is the waveform obtained by modulating the carrier waveform by the pulse envelope.

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.

The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.

A unitary projectile for an immobilization weapon and tethered by two electrical wires, has a plurality of electrical contacts including several contacts dispersed in a spaced pattern around the projectile after target impact. The pattern of several contacts substantially increases the probability that if the projectile hits the target, an immobilization circuit through the target will be completed. The deployment of the second contacts occurs as a result of the sudden deceleration of the projectile when it impacts the target or by the use of an additional spring-biased device. This simplifies the deployment as well as the projectile configuration and likely reduces the risk of misactivation or an ill-timed activation of the second contacts. In a preferred version of the disclosed embodiments, each projectile has its own electrical contact which forms one of the two polarities of the electrical discharge. In addition, there are preferably four second polarity contacts dispersed in a symmetrical arrangement around the projectile.

In the photovoltaic devices comprising a substantially intrinsic amorphous silicon layer containing hydrogen between an n-type single-crystal silicon substrate and a p-type amorphous silicon layer containing hydrogen, the photovoltaic device according to the present invention comprises a trap layer that contains less hydrogen than the intrinsic amorphous silicon layer between the p-type amorphous silicon layer and the intrinsic amorphous silicon layer. The trap layer reduces hydrogen diffusion from the intrinsic amorphous silicon layer to the p-type amorphous silicon layer.

Tissue engineering methods and biochamber apparatus are provided for making tissue grafts for implantation into a patient. The methods include applying a sustained low magnitude pressure gradient transmurally across a permeable scaffold material using a media containing cells, preferably microvascular epithelial cells, to be deposited on the scaffold for the production of tissue grafts, preferably vascular grafts, to promote accelerated adhesion and maturation of cells on the scaffold material. Biochambers for preparing tubular tissue grafts are provided which contain connectors for holding a graft substrate, proximal and distal tubing for connection to an optional perfusion system, and structure for switching between transmural flow of a cell suspension across the graft substrate and translumenal flow through the lumen of the graft.

A versatile pest station for use with interchangeable inserts includes a housing, a lock mechanism, a first insert, and a second insert. The housing includes a base, a lid, and an opening. The base and the lid form a cavity, and the opening provides access to the cavity. The base has a bottom surface and is configured and arranged to be securely mounted to a surface. The lock mechanism interlocks the base and the lid. The first insert is configured and arranged to fit within the cavity, and the first insert includes an entrance mechanism. The second insert is configured and arranged to fit within the cavity, and the second insert includes a snap trap. The first insert and the second insert are interchangeable for individual use with the housing, and the first insert and the second insert are elevated relative to the bottom surface of the base.

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.

The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte / macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte / macrophage-type cells and / or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte / macrophage-type cells and / or reducing the production of inflammatory and pro-inflammatory mediators of these cells.

New methods for activating chromium catalysts for polymerization processes decrease the amount of time required for activation and increase catalyst activity. Rapid heating to a first temperature is followed by a first hold period before heating to a higher second temperature and maintaining the second temperature for a second hold period. In one aspect, the overall activation process takes less than 10 hours.

The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation.

Systems and methods for using virtual reality content as therapeutic treatment of psychological, psychiatric or medical conditions of a user are provided. The system may comprise a VR device for displaying the VR content to the user and one or more biometric monitors for monitoring the user's biometrics before, during and / or after exposure to the VR content. The system may further include a processor and one or more modules for analyzing the user's biometrics. The method may include the steps of measuring the user's initial biometric data, exposing the user to selected VR content, measuring the user's biometric data during and / or after exposure to the VR content, analyzing changes in the user's biometric data resulting from the selected VR content, determining whether the selected VR content as a positive effect on the psychological, psychiatric or medical condition of the user.

The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.